MAP2K7 and cutaneous melanoma: Clinically, some BRAFV600E-driven melanoma and advanced cutaneous melanoma demonstrate promising outcomes with immunotherapy (40, 41), yet others (phase II MSS mCRC study) show minor partial and no complete responses (42), underlying the need to explore additional combinations to enhance the efficacy of MEK inhibition.